Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
232 participants
INTERVENTIONAL
2021-09-17
2023-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
To this end, the primary objective is to compare the weight change rate (%) between the study groups compared to the placebo groups at week 56 after administration of the investigational product.
The secondary objective is to compare the weight change rate (%) at each evaluation point after administration of the investigational product, the proportions of subjects who lost more than 5% and more than 10% of weight at each evaluation point, and changes in weight/BMI/waist circumference/heart rate/blood pressure between the study groups compared to the placebo groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase IV Safety and Efficacy Study of VI-0521 in Adolescents With Obesity
NCT03922945
Effect of VI-0521 (Qsymia®) on Glomerular Filtration Rate (GFR) in Overweight or Obese Healthy Subjects
NCT02229214
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in People Who Are Overweight or Living With Obesity (OASIS 1)
NCT05035095
Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity
NCT05132088
Study to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients
NCT07009171
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active
1\. Administration of Qsymia 3.75mg/23mg once a daily for 2-week(W2), and then administration of Qsymia 7.5mg/46mg once a daily for 12-week(W14).
2-1. At W14, if the weight loss rate is 3% or more, administration of Qsymia 7.5mg/46mg once a daily by the end of visit(W56).
2-2. At W14, if the weight loss rate is NOT 3% or more, administration of Qsymia 11.25mg/69mg once a daily for 2-week(W16), and then administration of Qsymia 15mg/92mg once a daily by the end of visit(W56).
Qsymia 3.75Mg-23Mg Extended Release Capsule
From W0 to W2, once a daily.
Qsymia 7.5Mg-46Mg Extended Release Capsule
1. From W2 to W14, once a daily.
2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily.
Qsymia 11.25Mg-69Mg Extended Release Capsule
At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
Qsymia 15Mg-92Mg Extended Release Capsule
At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
Placebo
Administration of Qsymia placebo once a daily by the end of visit(W56).
Placebo
From W0(Randomisation) to W56(the End of visit) once a daily.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Qsymia 3.75Mg-23Mg Extended Release Capsule
From W0 to W2, once a daily.
Qsymia 7.5Mg-46Mg Extended Release Capsule
1. From W2 to W14, once a daily.
2. At W14, if the weight loss rate is 3% or more, from W14 to W56(the end of visit), once a daily.
Qsymia 11.25Mg-69Mg Extended Release Capsule
At W14, if the weight loss rate is NOT 3% or more, from W14 to W16, once a daily.
Qsymia 15Mg-92Mg Extended Release Capsule
At W14, if the weight loss rate is NOT 3% or more, from W16 to W56(the end of visit), once a daily.
Placebo
From W0(Randomisation) to W56(the End of visit) once a daily.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Obese patients with BMI ≥ 25 kg/m2 at screening visit and visit 2
3. Those who agreed to low-calorie regimen and exercise therapy during the study at screening visit
4. From screening visit prior to randomization visit (Visit 2), low-calorie regimen and exercise therapy compliances are all ≥ 70%
5. From screening visit prior to randomization visit (Visit 2), those who fails to lose weight by at least 10% due to a low-calorie regimen and exercise therapy.
6. Those who voluntarily decided to participate and gave written consent after being provided with and understanding the detailed explanation on this clinical trial
Exclusion Criteria
2. Thyroid dysfunction (hyperthyroidism, hypothyroidism) (however, for hypothyroidism, the case of taking therapeutic agents stably at least 3 months prior to the screening visit is allowed)
3. Arteriosclerosis patients with symptoms such as intermittent lameness and lower extremity pain
4. Patients with type 1 diabetes or those with type 2 diabetes who are taking diabetic medications other than metformin. (However, metformin is allowed only if it was administered without dose change 1 month prior to screening visit.)
5. Those who are taking monoamine oxidase (MAO) inhibitors at screening visit or who had taken less than 14 days before screening
6. Patients with SBP ≥ 160 mmHg, DBP ≥ 100 mmHg, or pulmonary hypertension at screening visit
7. A history of eating disorders, drug or alcohol abuse
8. A history of surgery for weight loss (e.g., bariatric surgery)
9. A weight change of \> 5kg within 3 months prior to the screening visit
10. A history of mental illness (e.g., bipolar disorder, depression, suicidal ideation, etc.)
11. Obesity due to endocrine disorders or genetic obesity
12. A history of kidney stones or gallbladder stones within 6 months of the screening visit
13. Patients who need to take furosemide (loop diuretic) or hydrochlorothiazide (thiazide-like diuretic) during the study (However, it is allowed only if it is administered for treatment of hypertension without dose change 3 months prior to screening visit.)
14. Patients with renal impairment (CrCl \< 60 mL/min)
15. Patients with hepatic impairment (AST, ALT ≥ 2.5 X ULN)
16. A history of treatment for transient ischemic attack (TIA), myocardial infarction, unstable angina, cerebral infarction, and cerebral hemorrhage, or angioplasty or coronary artery bypass grafting within 6 months prior to the screening visit (if it occurs before 6 months and is currently stable, it is possible to enroll)
17. Patients with severe heart failure (NYHA class III or higher), arrhythmia requiring treatment, and clinically significant heart valve disease
18. A history of anaphylaxis to active or minor ingredients of the investigational product
19. Hypersensitivity reaction or idiosyncrasy to sympathomimetic amine
20. A history of malignant tumor within 5 years prior to the screening visit (Surgery-resected basal cell carcinoma of the skin or squamous cell carcinoma of the skin or cervical intraepithelial neoplasia or thyroid cancer with no evidence of recurrence after 3 years of surgery are allowed)
21. Pregnant or lactating women
22. Those who disagree to the use of a medically acceptable contraception (see Section 14.1) during the study
23. A history of systemic steroid administration for 14 days or more within 3 months of screening visit
24. Within 3 months prior to the screening visit
* Taking Qsymia or
* Taking phentermine and topiramate in combination for weight loss or
* Taking phentermine or topiramate for other purposes
25. Taking other appetite suppressants (including herbal medicines) excluding Qsymia (or drugs containing active ingredient of Qsymia) within 6 months prior to the screening visit
26. Participation in other clinical trials within 3 months before the screening visit (participation is based on the last administration date of the investigational product)
27. Other cases where the investigator determined that the subject is ineligible for participation in the obesity clinical study based on the history of medical or surgical disease or laboratory test results
19 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Alvogen Korea
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ChangBeom Lee, M.D., Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Hanyang Univ. Guri Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KyungHee Univ. Hospital
Seoul, Dongdaemun-gu, South Korea
KyungHee Univ. Hospital at Gangdong
Seoul, Gangdong-gu, South Korea
The Catholic Univ. of Korea Bucheon St. Mary's Hospital
Bucheon-si, Gyeonggi-do, South Korea
Sejong Hospital
Bucheon-si, Gyeonggi-do, South Korea
Hanyang Univ. Guri Hospital
Guri-si, Gyeonggi-do, South Korea
Gil Hospital
Incheon, Namdong-gu, South Korea
GangNeung Asan Hospital
Gangneung, Sacheon-myeon, South Korea
Severance Hospital
Seoul, Seodaemun-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
20-119
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.